Annovis Bio, Inc. develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. News about ANVS commonly centers on clinical development of buntanetap, peer-reviewed publications, biomarker data, safety findings, and scientific presentations related to the company’s multi-protein approach to neurodegeneration.
Recurring updates also cover intellectual-property protection for buntanetap and related compounds, collaborations that add digital biomarker technology to Parkinson’s disease research, corporate financing, annual financial results, and other public-company developments tied to funding, governance, and clinical-regulatory disclosure.
On November 16, 2020, Annovis Bio (NYSE American: ANVS) announced its participation in the A.G.P. Virtual Healthcare Symposium scheduled for November 19, 2020. CEO Maria Maccecchini, Ph.D., and CFO Jeff McGroarty, MBA, CPA, will host one-on-one meetings with investors to discuss the company's development pipeline and milestones. Annovis is focused on treating neurodegenerative diseases, including Alzheimer's, Parkinson's, and Alzheimer's in Down Syndrome, with ongoing Phase 2a studies aimed at improving memory and function. Interested investors can register for meetings through A.G.P.
On November 12, 2020, Annovis Bio Inc. (ANVS) announced the successful completion of its dog cohort in a chronic toxicology study for its lead compound, ANVS401, aimed at treating Alzheimer’s and Parkinson’s diseases. Funded by a $1.9 million NIH grant, the nine-month study reported no negative side effects, reinforcing previous positive safety findings. CEO Maria Maccecchini highlighted this as a crucial milestone for enabling long-term human trials, with interim data from ongoing Phase 2a trials expected in Q1 2021.
Annovis Bio Inc. (NYSE American: ANVS) announced that its CEO, Dr. Maria Maccecchini, will present at the Meridian Clinical Trials Summit on November 2, 2020. Her presentation will focus on strategies for de-risking Phase 3 clinical studies using insights from ongoing Phase 2a trials for Alzheimer's and Parkinson's diseases. Dr. Maccecchini aims to demonstrate how the lead compound, ANVS401, can potentially reverse toxic neural effects and restore brain function. The company is developing therapies targeting multiple neurotoxic proteins to improve cognitive and bodily functions affected by these diseases.
On October 29, 2020, Annovis Bio (NYSE American: ANVS) announced the resumption of its Phase 2a clinical trial for ANVS401, targeting early Alzheimer's disease (AD) patients. This follows a suspension due to COVID-19 in March 2020. The trial includes 24 participants across six U.S. sites, with 15 patients already treated. Data is anticipated in 2021. CEO Maria Maccecchini expressed optimism about the drug's ability to enhance axonal transport and improve cognitive function, despite pandemic-related delays in broader clinical trials.
Annovis Bio Inc. (NYSE American: ANVS) announced that its Founder and CEO, Maria Maccecchini, Ph.D., will receive the 2020 Smart Business Dealmaker Award at the Smart Business Dealmakers Conference on October 22. Dr. Maccecchini expressed gratitude for the recognition and highlighted the team's efforts that contributed to the company’s successful IPO earlier this year. Annovis Bio is focused on treating neurodegenerative diseases, including Alzheimer's and Parkinson's, and is currently conducting Phase 2a studies on its treatments. The award ceremony runs from 12:30 PM to 1:00 PM ET.
On October 20, 2020, Annovis Bio (NYSE American: ANVS) announced participation by CEO Maria Maccecchini, Ph.D., in the Financial Times' Outstanding Director Exchange (ODX) Roundtable, discussing the evolving relationship between pharma and biotech. She will also join the Angel Venture Fair Women’s Founders and Funders panel. With extensive experience since 1992, Dr. Maccecchini aims to share insights beneficial to directors and aspiring women entrepreneurs. Annovis specializes in treatments for Alzheimer’s and Parkinson’s diseases, with ongoing clinical studies aimed at improving cognitive and motor functions.
On October 15, 2020, Annovis Bio Inc. (ANVS) reported significant advancements in its business operations for Q3 2020. The company announced the initiation of a Phase 2a clinical study for its lead compound, ANVS401, targeting Alzheimer’s and Parkinson’s diseases, with preliminary data expected in early 2021. Annovis Bio also restarted a previously halted Alzheimer's study, completed a chronic toxicology study with favorable safety results, and published three scientific papers corroborating its findings. Additionally, the company secured two patents and filed five more related to treatments for neurodegenerative diseases.
On October 12, 2020, Annovis Bio (NYSE American: ANVS) announced that its CEO, Maria Maccecchini, will present at the 2020 BIO Investor Forum, taking place October 13-15, 2020, in a digital format. The presentation will be available on demand for registered attendees. Annovis Bio focuses on developing treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD), and Alzheimer’s in Down Syndrome (AD-DS), targeting neurotoxic proteins to enhance nerve cell function. For further information, visit www.annovisbio.com.
On September 3, 2020, Annovis Bio Inc. (NYSE American: ANVS) announced a televised interview with CEO Maria Maccecchini, airing on The RedChip Money Report on September 6 at 6 p.m. local time. The interview will discuss the Company's innovative approach to treating neurodegenerative diseases, including ongoing Phase 2a studies in Alzheimer’s and Parkinson’s diseases. Additionally, viewers can catch the program in the U.S. on the Action Channel. Annovis focuses on multi-target solutions for neurodegeneration, aiming to improve conditions like memory loss associated with Alzheimer's.
On September 1, 2020, Annovis Bio Inc. (ANVS) announced the dosing of the first three patients in its Phase 2a clinical trial for Alzheimer’s disease (AD) and Parkinson’s disease (PD). The trial, which has IRB approval, will enroll a total of 28 patients over four weeks, focusing on the drug ANVS401's ability to reverse toxic nerve cell death. Initial data is expected in early 2021, followed by a larger dose-response trial. This is a significant milestone for the company, which aims to offer a novel treatment for these neurodegenerative diseases.